Supplement

You have full text access to this OnlineOpen article

HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women†

  1. Maura L. Gillison MD, PhD1,‡,§,*,
  2. Anil K. Chaturvedi PhD2,
  3. Douglas R. Lowy MD3,¶

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23764

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 3036–3046, 15 November 2008

Additional Information

How to Cite

Gillison, M. L., Chaturvedi, A. K. and Lowy, D. R. (2008), HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer, 113: 3036–3046. doi: 10.1002/cncr.23764

Author Information

  1. 1

    Division of Viral Oncology, Johns Hopkins, Kimmel Cancer Center, Baltimore, Maryland

  2. 2

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland

  3. 3

    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

  1. ‡

    Dr. Gillison has received research funding from Merck.

  2. §

    Fax: (410) 614-9334.

  3. Dr. Lowy reports that he is a named inventor on US government-owned HPV vaccine patents that are licensed to GlaxoSmithKline and Merck, the commercial manufacturers of HPV vaccines, and is entitled to limited royalties as specified by federal law.

*Johns Hopkins University, Cancer Research Bldg. I, Rm. 3M 54A, 1650 Orleans Street, Baltimore, MD 21231;

  1. †

    The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Centers for Disease Control and Prevention.This is a US government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 15 JUN 2008
  4. Manuscript Revised: 5 JUN 2008
  5. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (177K)

REFERENCES

  • 1
    Clifford GM,Smith JS,Plummer M,Munoz N,Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003; 88: 63–73.
  • 2
    Paavonen J,Jenkins D,Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 2161–2170.
  • 3
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915–1927.
  • 4
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43–66.
    Direct Link:
  • 5
    Goldhaber-Fiebert JD,Stout NK,Ortendahl J,Kuntz KM,Goldie SJ,Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007; 5: 11.
  • 6
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890–907.
  • 7
    Walboomers JM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–19.
    Direct Link:
  • 8
    Gillison ML,Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr. 2003; 57–65.
  • 9
    IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Paris, France: IARC; 2007.
  • 10
    Chin-Hong PV,Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002; 35: 1127–1134.
  • 11
    Garland SM,Hernandez-Avila M,Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928–1943.
  • 12
    Dunne EF,Unger ER,Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813–819.
  • 13
    de Sanjose S,Diaz M,Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7: 453–459.
  • 14
    Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965; 58: 295–300.
  • 15
    Crum CP,McLachlin CM,Tate JE,Mutter GL. Pathobiology of vulvar squamous neoplasia. Curr Opin Obstet Gynecol. 1997; 9: 63–69.
  • 16
    Monk BJ,Burger RA,Lin F,Parham G,Vasilev SA,Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol. 1995; 85: 709–715.
  • 17
    Hildesheim A,Han CL,Brinton LA,Kurman RJ,Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol. 1997; 90: 748–754.
  • 18
    Brinton LA,Nasca PC,Mallin K,Baptiste MS,Wilbanks GD,Richart RM. Case-control study of cancer of the vulva. Obstet Gynecol. 1990; 75: 859–866.
  • 19
    Kurman RJ,Toki T,Schiffman MH. Basaloid and warty carcinomas of the vulva. Distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol. 1993; 17: 133–145.
  • 20
    Trimble CL,Hildesheim A,Brinton LA,Shah KV,Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol. 1996; 87: 59–64.
  • 21
    D'Souza G,Kreimer AR,Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. NEngl J Med. 2007; 356: 1944–1956.
  • 22
    Gillison ML,Koch WM,Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709–720.
  • 23
    Flowers LC,Wistuba II,Scurry J, et al. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. J Soc Gyneco Investig. 1999; 6: 213–221.
  • 24
    Riethdorf S,Neffen EF,Cviko A,Loning T,Crum CP,Riethdorf L. p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol. 2004; 35: 1477–1483.
  • 25
    Santos M,Landolfi S,Olivella A, et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol. 2006; 30: 1347–1356.
  • 26
    Begum S,Gillison ML,Ansari-Lari MA,Shah K,Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res. 2003; 9: 6469–6475.
  • 27
    Klussmann JP,Gultekin E,Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003; 162: 747–753.
  • 28
    Ragin CC,Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007; 121: 1813–1820.
    Direct Link:
  • 29
    Pinto AP,Schlecht NF,Pintos J, et al. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol Oncol. 2004; 92: 856–865.
  • 30
    Lerma E,Matias-Guiu X,Lee SJ,Prat J. Squamous cell carcinoma of the vulva: study of ploidy, HPV, p53, and pRb. Int J Gynecol Pathol. 1999; 18: 191–197.
  • 31
    Knopp S,Nesland JM,Trope C,Holm R. p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol. 2006; 126: 266–276.
  • 32
    Bezerra AL,Lopes A,Landman G,Alencar GN,Torloni H,Villa LL. Clinicopathologic features and human papillomavirus dna prevalence of warty and squamous cell carcinoma of the penis. Am J Surg Pathol. 2001; 25: 673–678.
  • 33
    Bezerra AL,Lopes A,Santiago GH,Ribeiro KC,Latorre MR,Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer. 2001; 91: 2315–2321.
    Direct Link:
  • 34
    Gross G,Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol. 2004; 193: 35–44.
  • 35
    Heideman DA,Waterboer T,Pawlita M, et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol. 2007; 25: 4550–4556.
  • 36
    Lont AP,Kroon BK,Horenblas S, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer. 2006; 119: 1078–1081.
    Direct Link:
  • 37
    Higgins GD,Uzelin DM,Phillips GE,Villa LL,Burrell CJ. Differing prevalence of human papillomavirus RNA in penile dysplasias and carcinomas may reflect differing etiologies. Am J Clin Pathol. 1992; 97: 272–278.
  • 38
    Brinton LA,Li JY,Rong SD, et al. Risk factors for penile cancer: results from a case-control study in China. Int J Cancer. 1991; 47: 504–509.
    Direct Link:
  • 39
    Maden C,Sherman KJ,Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst. 1993; 85: 19–24.
  • 40
    Gregoire L,Cubilla AL,Reuter VE,Haas GP,Lancaster WD. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst. 1995; 87: 1705–1709.
  • 41
    Rubin MA,Kleter B,Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001; 159: 1211–1218.
  • 42
    Ferreux E,Lont AP,Horenblas S, et al. Evidence for at least 3 alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, 1 of which is mediated by high-risk human papillomavirus. J Pathol. 2003; 201: 109–118.
    Direct Link:
  • 43
    Heino P,Goldman S,Lagerstedt U,Dillner J. Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma. Int J Cancer. 1993; 53: 377–381.
    Direct Link:
  • 44
    Frisch M,Glimelius B,van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997; 337: 1350–1358.
  • 45
    Daling JR,Weiss NS,Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987; 317: 973–977.
  • 46
    Hampl M,Wentzensen N,Vinokurova S, et al. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res. Clin Oncol. 2007; 133: 235–245.
  • 47
    Hellman K,Silfversward C,Nilsson B,Hellstrom AC,Frankendal B,Pettersson F. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-96. Int J Gynecol Cancer. 2004; 14: 491–501.
    Direct Link:
  • 48
    Smeets SJ,Hesselink AT,Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007; 121: 2465–2472.
    Direct Link:
  • 49
    Chaturvedi AK,Engels EA,Anderson WF,Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26: 612–619.
  • 50
    Johnson LG,Madeleine MM,Newcomer LM,Schwartz SM,Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004; 101: 281–288.
    Direct Link:
  • 51
    Judson PL,Habermann EB,Baxter NN,Durham SB,Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006; 107: 1018–1022.
  • 52
    Barnholtz-Sloan JS,Maldonado JL,Pow-sang J,Giuliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007; 25: 361–367.
  • 53
    Reisinger KS,Block SL,Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007; 26: 201–209.
  • 54
    Stanley M,Lowy DR,Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine. 2006; 24( suppl 3): S106–S113.
  • 55
    Herrero R,Castellsague X,Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003; 95: 1772–1783.
  • 56
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467–475.
  • 57
    Kreimer AR,Alberg AJ,Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis. 2004; 189: 686–698.
  • 58
    Parkin DM,Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;(24 suppl 3 ): S11–S25.
  • 59
    Watson M,Saraiya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 2941–2954.
  • 60
    Fakhry C,Westra WH,Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261–269.
  • 61
    Clifford G,Franceschi S,Diaz M,Munoz N,Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24( suppl 3): S26–S34.
  • 62
    Daling JR,Madeleine MM,Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004; 101: 270–280.
    Direct Link:
  • 63
    Madeleine MM,Daling JR,Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst. 1997; 89: 1516–1523.
  • 64
    Daling JR,Madeleine MM,Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84: 263–270.
  • 65
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2006 Sub (1973-2004)-Linked to County Attributes-Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. Atlanta, GA: SEER; 2007.
  • 66
    Joseph DA,Miller JW,Wu XC, et al. Understanding the burden of HPV-associated anal cancers in the United States. Cancer. 2008; 113( 10 suppl): 2892–2900.
    Direct Link:
  • 67
    Ryerson BA,Peters ES,Coughlin SS, et al. Burden of potentially HPV-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer. 2008; 113( 10 suppl): 2901–2909.
    Direct Link:
  • 68
    Hernandez BY,Barnholtz-Sloan J,German RR, et al. Burden of penile cancer in the United States. Cancer. 2008; 113( 10 suppl): 2883–2891.
    Direct Link:
  • 69
    Wu XC,Matanoski G,Chen VW, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer. 2008; 113( 10 suppl): 2873–2882.
    Direct Link:
  • 70
    Saraiya M,Watson M,Wu XC, et al. Incidence of in situ and invasive vulvar cancer in the United States, 1998-2003. Cancer. 2008; 113( 10 suppl): 2865–2872.
    Direct Link:
View Full Article (HTML) Get PDF (177K)